Moss T J, Fonkalsrud E W, Feig S A, Lenarsky C, Selch M, Wells J, Seeger R C
Department of Pediatrics, UCLA School of Medicine 90024.
Ann Surg. 1987 Oct;206(4):514-20. doi: 10.1097/00000658-198710000-00012.
From 1983 to 1986, 21 patients with poor prognosis neuroblastoma were treated with bone marrow transplantation. This regimen included induction chemotherapy, delayed surgical resection, local irradiation, and intensive chemoradiotherapy followed by infusion of allogeneic or autologous marrow. This therapeutic approach resulted in a 57% long-term survival rate (follow-up: 14-48 months), which appears to be approximately three times superior to conventional chemotherapy in a comparable group of children. In addition, complete resection was possible in 11 of 17 patients operated on after induction therapy. Recurrence in the primary site after bone marrow transplantation occurred in only one of 18 evaluable patients. Thus, this approach almost always eradicates primary tumor in patients with neuroblastoma with advanced disease.
1983年至1986年，21例预后不良的神经母细胞瘤患者接受了骨髓移植治疗。该方案包括诱导化疗、延迟手术切除、局部放疗、强化放化疗，随后输注异体或自体骨髓。这种治疗方法导致长期生存率为57%（随访时间：14 - 48个月），在一组可比的儿童中，这一生存率似乎比传统化疗高出约三倍。此外，17例诱导治疗后接受手术的患者中有11例实现了完全切除。在18例可评估的患者中，仅有1例在骨髓移植后出现原发部位复发。因此，这种方法几乎总能根除晚期神经母细胞瘤患者的原发肿瘤。
